Pivot to Growth: The Acceleration Phase

Teva scientist looking at stylized DNA strand representing acceleration phase of pivot to growth strategy

February 17, 2026

Teva’s Pivot to Growth strategy is reshaping the company’s future. As of the end of 2025, Teva has delivered 3 consecutive years of growth, supported by a robust pipeline, and a clear forward vision. At a recent strategy day presentation to industry professionals, CEO Richard Francis explains why now is the time to accelerate.

Progress so far

In May 2023, Teva President and CEO Richard Francis revealed the company’s Pivot to Growth strategy. Two years on, its successful execution has been clearly demonstrated:

11 consecutive quarters of growth as of Q2 2025
A strong financial performance, with 2024 revenues of $16.5 billion* for the full year reflecting a 6% overall increase
Global sales of $3.9 billion for the first three months of 2025* are 5% up on the previous year’s first quarter.

CEO perspective

richard-francis-ceo-teva-pharmaceutical-industries-teva-pipeline-potential — "Teva is a very different company than it was two years ago. We have sustainable growth. We have a world-class, late-stage pipeline. We have a good cash flow. We are moving from a world-class generics company to a world-class biopharma company enabled by generics."

Richard Francis, Teva President and CEO

Our Pivot to Growth strategy is clear

Teva will continue to grow through 2027 driven by our innovative portfolio, drive a stable and cash-generating generics powerhouse and modernize the organization. We will accelerate growth beyond 2027 with our innovative pipeline.

The four pillars of Pivot to Growth

Pivot to Growth is not a tagline, it’s a detailed strategy built on four pillars:

Deliver on growth engines and support patients with conditions including schizophrenia, migraine and involuntary movement disorders.

Teva has accelerated its innovative portfolio to $2.3 billion, representing 30% core growth over the last two years. Read more: Deliver on Growth Engines

Step up innovation by working on breakthrough treatments for diseases that are on the rise worldwide, such as inflammatory bowel disease (IBD), asthma and rheumatoid arthritis. The last two years have seen several new treatment launches and positive results for treatments in clinical trials at Teva. Read more: Step Up Innovation

Sustain Teva’s position as a generics powerhouse and continue to provide affordable medicines globally. Teva’s generics business has grown by 5% across all regions since 2023. Read more: Generics Powerhouse and Access to Medicines

Focus Teva’s business towards growth drivers by optimizing its portfolio and modernizing operations. Demonstrated by Teva’s transformation through its Pivot to Growth strategy.

What comes next?

Teva is a leading innovative biopharmaceutical company, enabled by our world-class generics business to reliably deliver medicines to patients worldwide. With a robust late-stage pipeline and a sharpened focus on innovation and execution, we’ve entered the Acceleration Phase of our Pivot to Growth strategy.

“The past two years have been about returning to growth and building a solid foundation. Today, Teva is a fundamentally different company, more focused, more innovative, and more robust. I am proud that we have consistently delivered on our commitments. Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio,” says Richard Francis.

“We are scaling our growth engines, modernizing our operations, and unlocking long-term value across every part of the business. In every dimension - commercial, scientific, operational, and financial - we are executing with clarity and confidence.”

Acceleration Phase priorities:

Innovative portfolio: continues to drive strong performance and future potential, aiming to build a >$5 billion innovative medicines franchise by 2030
Late-stage pipeline: includes treatments for IBD, asthma, schizophrenia, multiple system atrophy (MSA) and celiac disease
Biosimilars and OTC: a 13-strong biosimilars pipeline has the potential for 6 new launches by 2027, while a $1.1 billion OTC global business can achieve double-digit growth
2027 financial targets: reaffirmed targets include >$700 million in net savings and free cash flows of >$2.7 billion in 2027 and >$3.5 billion by 2030

Our strategy speaks to our Teva purpose – being all in for better health we work together to achieve remarkable things. Our direction is clear, and we are committed to keep raising the bar, in service of our patients, customers and healthcare systems.

*All revenues in local currency terms

NPS-ALL-NP-01710 FEBRUARY 2026